Table 1 Demographic and disease characteristics for PsA patients
From: Differences in oxylipin profile in psoriasis versus psoriatic arthritis
Variable | Psoriatic arthritis (N=19) |
|---|---|
Age (years) (mean, SD) | 60.5 (± 11.4) |
Sex F:M | 7:12 (63.1% male) |
BMI (kg/m2) (mean, SD) | 31.9 (± 5.6) |
PsO (%) | 63.1% |
PASI | 3 (± 5.1) |
BSA (%) | 4.7 (± 11) |
TJC (mean, SD) | 9.3 (± 10.4) |
SJC (mean, SD) | 3.7 (4.2) |
VAS Activity (mean, SD) | 59.1 (± 28.7) |
VAS Pain (mean, SD) | 43.5 (± 32.2) |
Enthesitis (%) | 63.1% |
Enthesitis (mean, SD) | 2.2 (± 3) |
cDAPSA | 23.4 (11.4) |
NSAIDs (%) | 16.7% |
DMARDs (%) | 26.3% |
TNF alpha inhibitors (%) | 47.3% |
Corticosteroids (%) | 0 |
Topical corticosteroids (%) | 26.3% |